• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

系统性硬化症患者 MMP-7 水平升高:与肺部受累的相关性。

Elevated MMP-7 levels in patients with systemic sclerosis: correlation with pulmonary involvement.

出版信息

Exp Dermatol. 2011 Sep;20(9):770-3. doi: 10.1111/j.1600-0625.2011.01321.x. Epub 2011 Jun 26.

DOI:10.1111/j.1600-0625.2011.01321.x
PMID:21707759
Abstract

BACKGROUND

Fibrosis is characterized by an excessive accumulation of connective tissue because of an imbalance between synthesis and degradation of extracellular matrix proteins. Systemic sclerosis (SSc) is a prototypic chronic inflammatory disease leading to a severe fibrosis of the skin and many internal organs. QUESTIONS ADDRESSED: We investigated whether serum MMP-7 levels reflect the activity of the fibrotic reaction in systemic sclerosis.

EXPERIMENTAL DESIGN

Serum samples were obtained from 123 patients with systemic sclerosis. MMP-serum levels of all patients with SSc were compared with age-matched healthy controls.

RESULTS

Significantly increased median serum MMP-7 levels were found in patients with SSc when compared with controls. The median MMP-7 serum level of patients with lung fibrosis (LF) was significantly higher compared with those without LF. Accordingly, patients with dyspnea and DLCO (diffusion capacity of the lung for carbon monoxide) levels below 60% showed significantly higher median MMP-7 levels.

CONCLUSIONS

Elevated MMP-7 levels are associated with an advanced stage of SSc and LF. These data suggest that in SSc MMP-7 is involved in the process of fibrotic tissue remodelling.

摘要

背景

纤维化的特征是由于细胞外基质蛋白的合成和降解之间的失衡而导致的结缔组织过度积累。系统性硬化症(SSc)是一种典型的慢性炎症性疾病,导致皮肤和许多内部器官严重纤维化。

问题

我们研究了血清 MMP-7 水平是否反映系统性硬化症纤维化反应的活性。

实验设计

从 123 例系统性硬化症患者中获得血清样本。将所有 SSc 患者的 MMP-血清水平与年龄匹配的健康对照组进行比较。

结果

与对照组相比,SSc 患者的血清 MMP-7 水平明显升高。有肺纤维化(LF)的患者的血清 MMP-7 水平明显高于无 LF 的患者。因此,呼吸困难和 DLCO(一氧化碳扩散能力)水平低于 60%的患者的 MMP-7 水平明显升高。

结论

升高的 MMP-7 水平与 SSc 和 LF 的晚期阶段相关。这些数据表明,在 SSc 中,MMP-7 参与了纤维化组织重塑的过程。

相似文献

1
Elevated MMP-7 levels in patients with systemic sclerosis: correlation with pulmonary involvement.系统性硬化症患者 MMP-7 水平升高:与肺部受累的相关性。
Exp Dermatol. 2011 Sep;20(9):770-3. doi: 10.1111/j.1600-0625.2011.01321.x. Epub 2011 Jun 26.
2
Clinical significance of serum levels of matrix metalloproteinase-13 in patients with systemic sclerosis.系统性硬化症患者血清基质金属蛋白酶-13水平的临床意义
Rheumatology (Oxford). 2006 Mar;45(3):303-7. doi: 10.1093/rheumatology/kei143. Epub 2005 Nov 8.
3
Increased serum levels and tissue expression of matrix metalloproteinase-12 in patients with systemic sclerosis: correlation with severity of skin and pulmonary fibrosis and vascular damage.系统性硬化症患者血清基质金属蛋白酶-12 水平和组织表达增加:与皮肤和肺纤维化及血管损伤严重程度的相关性。
Ann Rheum Dis. 2012 Jun;71(6):1064-72. doi: 10.1136/annrheumdis-2011-200837. Epub 2012 Jan 17.
4
Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls.系统性硬化症患者、原发性雷诺现象患者及正常对照者的血清基质金属蛋白酶组织抑制因子-1、基质金属蛋白酶组织抑制因子-2和基质金属蛋白酶-1 。
Ann Rheum Dis. 2001 Sep;60(9):846-51.
5
Bronchoalveolar matrix metalloproteinase 9 relates to restrictive lung function impairment in systemic sclerosis.支气管肺泡基质金属蛋白酶9与系统性硬化症中的限制性肺功能损害有关。
Respir Med. 2007 Oct;101(10):2199-206. doi: 10.1016/j.rmed.2007.04.019. Epub 2007 Jul 20.
6
Elevated serum insulin-like growth factor (IGF-1) and IGF binding protein-3 levels in patients with systemic sclerosis: possible role in development of fibrosis.系统性硬化症患者血清胰岛素样生长因子(IGF-1)和IGF结合蛋白-3水平升高:在纤维化发展中的可能作用。
J Rheumatol. 2008 Dec;35(12):2363-71. doi: 10.3899/jrheum.080340. Epub 2008 Nov 1.
7
Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis.系统性硬化症患者血清肺及活化调节趋化因子/CCL18水平:活动性肺纤维化的敏感指标
Arthritis Rheum. 2005 Sep;52(9):2889-96. doi: 10.1002/art.21257.
8
Elevated serum concentrations of triggering receptor expressed on myeloid cells-1 in diffuse cutaneous systemic sclerosis: association with severity of pulmonary fibrosis.血清髓系细胞触发受体-1 水平升高与弥漫性皮肤系统性硬化症患者肺纤维化严重程度相关。
J Rheumatol. 2010 Apr;37(4):787-91. doi: 10.3899/jrheum.090664. Epub 2010 Feb 15.
9
[Systemic sclerosis and scleroderma circumscripta--disturbances of selected serum parameters which are responsible for vascular changes and CD34 expression in involved skin].[系统性硬化症和局限性硬皮病——参与皮肤中负责血管变化和CD34表达的特定血清参数紊乱]
Przegl Lek. 2009;66(12):1040-5.
10
Serum levels of matrix metalloproteinase-13 in patients with eosinophilic fasciitis.嗜酸性筋膜炎患者血清基质金属蛋白酶-13水平
J Dermatol. 2014 Aug;41(8):746-8. doi: 10.1111/1346-8138.12563. Epub 2014 Jul 16.

引用本文的文献

1
Insights into interstitial lung disease pathogenesis.间质性肺疾病发病机制的见解。
Breathe (Sheff). 2025 May 13;21(2):240261. doi: 10.1183/20734735.0261-2024. eCollection 2025 Apr.
2
Matrix metalloproteinases and their tissue inhibitors as upcoming biomarker signatures of connective tissue diseases-related interstitial lung disease: towards an earlier and accurate diagnosis.基质金属蛋白酶及其组织抑制剂作为结缔组织病相关间质性肺疾病即将出现的生物标志物特征:迈向更早、更准确的诊断
Mol Med. 2025 Feb 20;31(1):70. doi: 10.1186/s10020-025-01128-2.
3
Plasma Matrix Metalloproteinase Concentrations and Risk of Interstitial Lung Disease in a Prospective Rheumatoid Arthritis Cohort.
前瞻性类风湿关节炎队列中血浆基质金属蛋白酶浓度与间质性肺疾病风险
Arthritis Rheumatol. 2024 Jul;76(7):1013-1022. doi: 10.1002/art.42812. Epub 2024 Feb 15.
4
Umbilical-Cord-Derived Mesenchymal Stromal Cells Modulate 26 Out of 41 T Cell Subsets from Systemic Sclerosis Patients.脐带间充质基质细胞调节系统性硬化症患者41个T细胞亚群中的26个。
Biomedicines. 2023 Apr 30;11(5):1329. doi: 10.3390/biomedicines11051329.
5
Clinically Relevant Biomarkers in Connective Tissue Disease-Associated Interstitial Lung Disease.结缔组织病相关间质性肺疾病的临床相关生物标志物。
Immunol Allergy Clin North Am. 2023 May;43(2):411-433. doi: 10.1016/j.iac.2023.01.012. Epub 2023 Mar 3.
6
Recent innovations in the screening and diagnosis of systemic sclerosis-associated interstitial lung disease.系统性硬皮病相关间质性肺疾病的筛查和诊断的最新进展。
Expert Rev Clin Immunol. 2023 Jun;19(6):613-626. doi: 10.1080/1744666X.2023.2198212. Epub 2023 Apr 10.
7
Serum Biomarkers in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension.结缔组织病相关肺动脉高压的血清生物标志物。
Int J Mol Sci. 2023 Feb 20;24(4):4178. doi: 10.3390/ijms24044178.
8
Viewpoint: a multidisciplinary approach to the assessment of patients with systemic sclerosis-associated interstitial lung disease.观点:一种多学科方法评估系统性硬化症相关间质性肺疾病患者。
Clin Rheumatol. 2023 Mar;42(3):653-661. doi: 10.1007/s10067-022-06408-4. Epub 2022 Oct 21.
9
Syndrome of Combined Pulmonary Fibrosis and Emphysema: An Official ATS/ERS/JRS/ALAT Research Statement.特发性肺纤维化合并肺气肿综合征:美国胸科学会/欧洲呼吸学会/日本呼吸学会/拉丁美洲胸科学会联合官方声明。
Am J Respir Crit Care Med. 2022 Aug 15;206(4):e7-e41. doi: 10.1164/rccm.202206-1041ST.
10
Assessment of disease outcome measures in systemic sclerosis.系统性硬化病的疾病结局评估。
Nat Rev Rheumatol. 2022 Sep;18(9):527-541. doi: 10.1038/s41584-022-00803-6. Epub 2022 Jul 20.